US Patent

US12427104 — Injectable carboplatin formulations

Formulation · Assigned to Ingenus Pharmaceuticals LLC · Expires 2045-04-01 · 19y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects injectable formulations of carboplatin, specifically Paraplatin, with a pH of 5-7 and a dissolved oxygen level of at least 28 ppm.

USPTO Abstract

Described herein are injectable carboplatin formulations, comprising: about 10 mg/mL of carboplatin; and a pharmaceutically acceptable vehicle; wherein the formulation has a pH of from about 5 to about 7; wherein the formulation has a dissolved oxygen level of not less than about 28 ppm; wherein the formulation is filled in a vial at a fill volume of from about 1 mL to about 70 mL in a vial having a capacity of from about 1 mL to about 100 mL; wherein the vial has head space ranging from about 20% to about 82%; and wherein the headspace comprises oxygen gas in an amount effective to maintain a 1,1-cyclobutanedicarboxylic acid level of not more than 1.0%, based on the weight of carboplatin, and a total degradation impurity level at not more than 2.5%, based on the weight of carboplatin, when stored at room temperature for 24 months.

Drugs covered by this patent

Patent Metadata

Patent number
US12427104
Jurisdiction
US
Classification
Formulation
Expires
2045-04-01
Drug substance claim
No
Drug product claim
Yes
Assignee
Ingenus Pharmaceuticals LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.